Drugs that contain Drospirenone; Ethinyl Estradiol; Levomefolate Calcium
1. Beyaz patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6441168 | BAYER HLTHCARE | Stable crystalline salts of 5-methyltetrahydrofolic acid |
Jul, 2022
(1 year, 8 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE38253 | BAYER HLTHCARE | Composition for contraception |
Jun, 2014
(9 years ago) | |
| USRE37564 | BAYER HLTHCARE | Composition for contraception |
Jun, 2014
(9 years ago) | |
| USRE37838 | BAYER HLTHCARE | Composition for contraception |
Jun, 2014
(9 years ago) | |
| USRE43916 | BAYER HLTHCARE | Composition for contraception |
Jun, 2014
(9 years ago) | |
| US5798338 | BAYER HLTHCARE | Solid dosage forms that contain clathrates of 17α-ethinyl estradiol |
Jul, 2015
(8 years ago) | |
| US6958326 | BAYER HLTHCARE | Cyclodextrin-drospirenone inclusion complexes |
Dec, 2021
(2 years ago) | |
| US7163931 | BAYER HLTHCARE | Compositions of estrogen-cyclodextrin complexes |
Mar, 2022
(2 years ago) | |
| US8617597 | BAYER HLTHCARE | Pharmaceutical composition containing a tetrahydrofolic acid |
Feb, 2030
(5 years from now) | |
| US11617751 | BAYER HLTHCARE | Pharmaceutical composition containing a tetrahydrofolic acid |
Jul, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 24, 2013 |
| New Combination(NC) | Sep 24, 2013 |
Market Authorisation Date: 24 September, 2010
Treatment: Method of inducing contraception in a female of reproductive age who has not yet reached premenopause; Prevention of pregnancy; Treatment of mood changes and/or anxiety as symptoms of premenstrual dys...
Dosage: TABLET;ORAL
BEYAZ family patents
2. Safyral patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6441168 | BAYER HLTHCARE | Stable crystalline salts of 5-methyltetrahydrofolic acid |
Apr, 2020
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5798338 | BAYER HLTHCARE | Solid dosage forms that contain clathrates of 17α-ethinyl estradiol |
Jul, 2015
(8 years ago) | |
| US6958326 | BAYER HLTHCARE | Cyclodextrin-drospirenone inclusion complexes |
Dec, 2021
(2 years ago) | |
| US7163931 | BAYER HLTHCARE | Compositions of estrogen-cyclodextrin complexes |
Mar, 2022
(2 years ago) | |
| US8617597 | BAYER HLTHCARE | Pharmaceutical composition containing a tetrahydrofolic acid |
Feb, 2030
(5 years from now) | |
| US11617751 | BAYER HLTHCARE | Pharmaceutical composition containing a tetrahydrofolic acid |
Jul, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 16, 2013 |
Market Authorisation Date: 16 December, 2010
Treatment: Prevention of pregnancy; Raise folate levels in women who choose to use an oral contraceptive as their method of contraception for the purpose of reducing the risk of a neural tube defect in a pregnan...
Dosage: TABLET;ORAL
SAFYRAL family patents